SPARC
Sun Pharma Advanced Research Company Limited (SPARC) Stock Analysis
Sun Pharma Advanced Research Company Limited conducts novel drug discovery and development in chronic disease areas. It partners with Sun Pharma and third parties on clinical-stage compounds and licensing. The company invests in R&D for differentiated therapies. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹191.80
-2.53% 1W | +40.80% 52W
Market Cap
6.2k CR
P/E Ratio
3.9
52W High
₹289
52W Low
₹108
Div. Yield
0%
Beta
0.7
50 DMA
₹199
200 DMA
₹175.9
Profit Margin
83%
Inst. Own.
1.8%
📉 CONSOLIDATING DOWN
📉 CONSOLIDATING DOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 |
| Expenses | 126 | 113 | 116 | 122 | 110 | 116 | 89 | 80 | 62 | 74 | 65 | 80 | 74 |
| Operating Profit | -102 | -91 | -103 | -106 | -93 | -103 | -74 | -53 | -52 | -66 | -57 | 1,773 | -34 |
| OPM % | -427% | -432% | -740% | -639% | -555% | -800% | -494% | -196% | -540% | -836% | -670% | 96% | -85% |
| Other Income | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | -12 | 2 | 24 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Profit before tax | -95 | -86 | -100 | -105 | -96 | -107 | -79 | -61 | -52 | -76 | -80 | 1,761 | -21 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -1% | 0% | 0% | 0% | -0% | 1% |
| Net Profit | -95 | -86 | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 | -80 | 1,761 | -21 |
| EPS in Rs | -2.94 | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 | -0.64 |
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 239 | 76 | 72 | 1,879 | 1,909 |
| Expenses | 453 | 478 | 395 | 280 | 293 |
| Operating Profit | -214 | -402 | -323 | 1,599 | 1,617 |
| OPM % | -90% | -532% | -450% | 85% | 85% |
| Other Income | 11 | 29 | 2 | -2 | 13 |
| Interest | 8 | 2 | 9 | 34 | 36 |
| Depreciation | 12 | 13 | 12 | 10 | 10 |
| Profit before tax | -223 | -387 | -343 | 1,553 | 1,584 |
| Tax % | 0% | 0% | -0% | -0% | |
| Net Profit | -223 | -387 | -343 | 1,553 | 1,584 |
| EPS in Rs | -6.86 | -11.93 | -10.55 | 47.86 | 48.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 99.0% | – | – |
| Profit CAGR | 108.0% | – | – |
Shareholding Pattern
Promoters65.67%
FIIs1.76%
DIIs1.05%
Public31.52%
Promoters65.67%
FIIs2.04%
DIIs0.78%
Public31.51%
Promoters65.67%
FIIs2.04%
DIIs0.88%
Public31.41%
Promoters65.68%
FIIs3.90%
DIIs0.09%
Public30.34%
Promoters65.68%
FIIs3.74%
DIIs0.11%
Public30.48%
Promoters65.68%
FIIs3.64%
DIIs0.63%
Public30.04%
Promoters65.68%
FIIs3.24%
DIIs0.67%
Public30.41%
Promoters65.68%
FIIs1.45%
DIIs1.13%
Public31.76%
Promoters65.67%
FIIs2.04%
DIIs0.88%
Public31.41%
Promoters65.68%
FIIs3.74%
DIIs0.11%
Public30.48%
SPARC
Holdings Analysis
Key strengths & risk signals
57
Overall
44
Fundamental
71
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (189.1) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.0% (1 week), 3.5% (1 month), 24.7% (3 months).
Strengths (4)
EXCELLENT EFFICIENCY! 83.0% profit margin - company keeps strong profits.
BULLISH TREND! 50-day average (199.4) is above 200-day average (175.6) - positive signal.
GOOD YEAR! Stock gained 42.3% in the last year.
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
Fundamental & Technical Analysis
60Overall
44Fundamental
76Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -45.3% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
10/10
EXCELLENT EFFICIENCY! 83.0% profit margin - company keeps strong profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 29.99% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (199.0) is above 200-day average (175.9) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (191.8) above 200-day but below 50-day.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
10/10
GOOD YEAR! Stock gained 40.8% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 1,256,559 vs down days: 835,872. Ratio: 1.5x
RSI
3/5
NEUTRAL! RSI at 45.7 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 46.3% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.5% (1 week), 2.1% (1 month), 23.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPARC | ₹191.80 | 3.9 | 83.0% | -45.3% | – | +40.8% | 60 | CONSOLIDATING DOWN | -59.9% | -101.2% | +315.6% | -97.8% |
| IOLCP | ₹203.70 | 35.6 | 6.7% | 1.6% | -0.4% | +99.9% | 58 | BREAKDOWN | +90.0% | +21.1% | +37.1% | +22.1% |
| INNOVACAP | ₹1,053.40 | 39.1 | 8.8% | 20.1% | 27.5% | +30.4% | 73 | BREAKDOWN | +42.3% | +15.7% | +34.0% | +5.2% |
| FDC | ₹348.60 | 19.4 | 13.4% | 6.8% | 13.2% | -21.8% | 72 | BREAKOUT | +9.1% | +28.1% | +3.0% | +14.2% |
| BLISSGVS | ₹660.70 | 52.4 | 13.5% | 7.2% | 22.1% | +342.5% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| MOREPENLAB | ₹128.30 | 50.1 | 7.2% | 8.4% | 34.9% | +154.1% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| GUJTHEM | ₹389.10 | 87.3 | 28.0% | 3.8% | -7.0% | -13.6% | 56 | BREAKDOWN | +22.0% | +1.8% | +22.0% | -0.9% |
| AARTIPHARM | ₹867.60 | 36.9 | 10.4% | -2.6% | -3.3% | +7.1% | 54 | APPROACHING RESISTANCE | +65.4% | +24.5% | +38.7% | -8.0% |
Data from TradeAlone · Updated daily
SPARC News
Sun Pharma Advanced Research Company Limited (NSE: SPARC) breaks below support, falls 8% intraday2026-07-17Sun Pharma Advanced Research Company Limited (SPARC) cools off after resistance breakout, down 5%2026-07-10Sun Pharma Advanced Research Company Limited (NSE: SPARC) gains 5% intraday, tests resistance2026-07-08Sun Pharma Advanced Research Company Limited (NSE: SPARC) gains 10% intraday, nears resistance at ₹2662026-07-06Sun Pharma Advanced Research Company Limited (NSE: SPARC) extends gains, moves up 5% intraday2026-07-06Sun Pharma Advanced Research Company Limited (NSE: SPARC) extends gains, moves up 5% intraday2026-06-24
